The translational gap for gene therapies in low- and middle-income countries.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
08 May 2024
Historique:
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 8 5 2024
Statut: ppublish

Résumé

Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the potential to become safe and effective treatment options for a wide range of genetic and nongenetic diseases. However, as the medical scope of gene therapies expands, consideration must be given to those who will benefit and what proactive steps must be taken to widen development and access potential, particularly in regions carrying a high disease burden.

Identifiants

pubmed: 38718130
doi: 10.1126/scitranslmed.adn1902
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadn1902

Auteurs

Kevin W Doxzen (KW)

Strategic Analysis Inc., Arlington, VA, USA.

Jennifer E Adair (JE)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Departments of Medical Oncology and Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.

Yris Maria Fonseca Bazzo (YM)

Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Brasília, Brasília, DF, Brazil.

Daima Bukini (D)

Sickle Cell Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health & Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania.
SickleInAfrica Clinical Coordinating Center, Muhimbili University of Health & Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania.

Kenneth Cornetta (K)

Indiana University School of Medicine, Indianapolis, IN, USA.

Varsha Dalal (V)

Department of Health Research, Ministry of Health and Family Welfare, Government of India, New Delhi, India.

Renato Luiz Guerino-Cunha (RL)

Centro Paulista de Oncologia, Grupo Oncoclínicas, São Paulo, SP, Brazil.
Instituto Oncoclínicas, Rio de Janeiro, RJ, Brazil.

Suradej Hongeng (S)

Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Geeta Jotwani (G)

Indian Council of Medical Research, New Delhi, India.

Cissy Kityo-Mutuluuza (C)

Joint Clinical Research Centre (JCRC), Kampala, Uganda.

Krishnamurti Lakshmanan (K)

Department of Pediatric Hematology and Oncology, Yale School of Medicine, New Haven, CT, USA.

Johnny Mahlangu (J)

Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa.

Julie Makani (J)

Sickle Cell Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health & Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania.
SickleInAfrica Clinical Coordinating Center, Muhimbili University of Health & Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania.
Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.

Vikram Mathews (V)

Department of Haematology, Christian Medical College (CMC), Vellore, India.

Margareth C Ozelo (MC)

INCT Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil.

Savita Rangarajan (S)

Advanced Center for Oncology, Haematology & Rare Disorders (ACOHRD), K. J. Somaiya Medical College & Research Center, Somaiya Ayurvihar, Mumbai, Maharashtra, India.
Faculty of Medicine, University of Southampton, Southampton, UK.

Janine Scholefield (J)

Bioengineering and Integrated Genomics Group, Next Generation Health Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

João Batista Silva Júnior (J)

Brazilian Health Regulatory Agency-ANVISA, Brasília, DF, Brazil.
Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Brasília, Brasília, DF, Brazil.

Joseph M McCune (JM)

HIV Frontiers, Global Health Accelerator, Bill & Melinda Gates Foundation, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH